SeaStar Medical Highlights $69,146 Cost Savings With QUELIMMUNE Therapy In Pediatric AKI, Published In Journal Of Medical Economics

Author: Benzinga Newsdesk | September 02, 2025 08:23am

SeaStar Medical Holding Corporation (NASDAQ:ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life announced today the publication of a health economic analysis estimating significant cost savings with the use of the QUELIMMUNE therapy in pediatric patients with Acute Kidney Injury (AKI) in the ICU setting. The analysis, as presented in the Journal of Medical Economics (IJME) estimates a cost savings of $69,146 per hospitalization when the QUELIMMUNE therapy is administered compared to modeled hospitalization costs with standard continuous renal replacement therapy (CRRT). These projected savings are estimated to offset the cost of the QUELIMMUNE therapy with a potential for institutions to incur no out-of-pocket costs for 6 days (median duration) of treatment of pediatric AKI.

Posted In: ICU